Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Suiqiong Li · DL ADV-TECH, LLC · 2021 · $242,132 — Summary/Abstract: The availability of COVID-19 vaccines is a significant step in ending this pandemic and returning life to normal. Successfully vaccination should induce sufficient titers of specific neutralizing antibodies (nAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…
THOMAS T PERLS · BOSTON UNIVERSITY MEDICAL CAMPUS · 2021 · $337,810 — Assessing accuracy of protein measurements across multiple analytical platforms. Our NIA funded project, UH2AG064704 “Identifying protective omics profiles in centenarians and translating these into preventive and therapeutic strategies”, is a phased UH2/UH3 project. We are currently in the UH2 phas…
Julie Champion · GEORGIA INSTITUTE OF TECHNOLOGY · 2021 · $397,382 — Abstract SARS-CoV-2 has spread rapidly across the globe. While vaccines are in development and existing drugs have shown some efficacy in reducing disease severity, there is an urgent need for molecules that can serve in both a prophylactic and therapeutic function. Proteins are well suited for this…
Melodie Lynn Weller · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2021 · $228,750 — Project Summary | Role of Salivary Gland Localized SARS-CoV-2 Infection in Oral Tolerance & Immunization Efficacy Over 5 million individuals in the United States have been diagnosed with systemic acute respiratory syndrome coronavirus-2, SARS-CoV-2, infections 1. One of the primary unanswered quest…
John R Cirrito · WASHINGTON UNIVERSITY · 2021 · $433,266 — ABSTRACT/PROJECT SUMMARY Coronavirus 2019 (COVID-19) has afflicted 6.2 million Americans and killed 190,000 as of early September 2020 (WHO website); a roughly 3% mortality. Between a shortage in testing and unidentified asymptomatic individuals, the actual number of those infected could be 6 to 24…
Wonpil Im · LEHIGH UNIVERSITY · 2021 · $199,748 — PROJECT SUMMARY/ABSTRACT The current pandemic of Coronavirus Disease-2019 (COVID-19) has had devastating impacts across the world. In order to enter human host cells, SARS-CoV-2, the virus causing COVID-19, uses its surface spike (S) protein to attach to host cell surface receptors. Besides the best…
Wei-chiao Huang · POP BIOTECHNOLOGIES, INC · 2021 · $299,991 — PROJECT SUMMARY The coronavirus disease 2019 (COVID-19) global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is unprecedented in our lifetime and has caused major social, economic and human suffering. Globally, there have been 76,858,506 confirmed cases, leading to …
Pamela J Bjorkman · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2021 · $410,750 — Summary The rapid mutation rate of HIV-1 results in many thousands of viral strains, thus thwarting current vaccine efforts. Although HIV-1 infection can be controlled by anti-retroviral therapy (ART), the virus rebounds within weeks of ART cessation because complete elimination of HIV-1 is prevente…
Susan Daniel · CORNELL UNIVERSITY · 2021 · $174,298 — Project Summary / Abstract Enveloped viruses access their host cells by binding to receptors on the plasma membrane and then undergoing fusion with the host membrane. Both binding and fusion are mediated by a specific viral “spike” protein that is typically primed for fusion activation by proteolyti…
Richard J. Kuhn · PURDUE UNIVERSITY · 2021 · $30,170 — PROJECT SUMMARY This proposal aims to rapidly generate vaccine candidates against the 2019 novel coronavirus SARS-CoV- 2. Since its emergence about three months ago, this virus has caused more than 120,000 infections and 4,300 deaths worldwide and is rapidly spreading to virtually every country inc…
Paul John Norman · UNIVERSITY OF COLORADO DENVER · 2021 · $742,765 — Summary To ensure a successful and sustained response to the COVID-19 crisis it becomes imperative that the functional implications of the considerable genotypic and phenotypic variation in natural human immunity are understood. Natural killer (NK) cells have major roles in controlling the innate an…
JOHN S. LAZO · KEVIRX INC. · 2021 · $252,208 — The Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) is responsible for the current COVID-19 pandemic. SAR-CoV-2, like other coronaviruses, infects human airways and enters cells via its S (Spike) protein, which binds to the human angiotensin-converting enzyme 2 (ACE2) and is primed by the…
Kathryn M. Anastos · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2021 · $40,374 — COVID Vaccine Study Supplement to MWCCS Principal Investigators: C. Rinaldo and J. Martinson Innovation Fund Application to the Multicenter AIDS Cohort Study (MACS)/Women’s Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS): COVID-19 Vaccine Acceptance and Hesitancy (CVHB) Study in People wi…
JOHN P MOORE · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $680,752 — Overall Abstract This HIVRAD Program Project renewal application is made in response to PAR-18-319. It contains two Research Projects, one Scientific Core and an Administrative Core, under the direction of Principal Investigator, John P. Moore, PhD (Weill Cornell Medical College; WCMC) and co-Princi…
MARK ROBERTS LOONEY · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $623,280 — Project Summary/Abstract The acute respiratory distress syndrome (ARDS) was first formally described in 1967, but it has likely been the predominant cause of death in pandemic viral infections for centuries. Now, the world is at grips with a new pandemic from SARS-CoV-2, or COVID-19, which has infec…
EVAN J ANDERSON · EMORY UNIVERSITY · 2021 · $1,169,796 — Summary/Abstract The Emory VTEU will participate in DMID 21-0012, A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines. Knowledge of the safety, tolerability, and immunogenicity of SARS-CoV-2 delayed homologous and heterologous boost vaccine incor…
Gary R Whittaker · CORNELL UNIVERSITY · 2021 · $196,250 — Project Summary/Abstract We propose to develop a subunit vaccine for SARS-CoV-2, using a structure-based approach targeting conserved and functionally essential domains in the stalk region of the viral spike protein. We expect our vaccine platform to be applicable and effective across a wide range o…
SUNDARAM RAMAKRISHNAN · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2021 · $153,500 — Project Summary Infection with Covid-19 has reached pandemic status with more than 125 million confirmed cases and 2.75 million deaths making it one of the most deadliest pandemics in history. It is associated with severe acute respiratory syndrome symptoms with high fatality rates. SARS-CoV-2 infec…
Anil Prasad · BETH ISRAEL DEACONESS MEDICAL CENTER · 2021 · $78,750 — Abstract: Endothelial injury is hypothesized to importantly contribute to the respiratory failure and thromboemboli seen in COVID-19. Yet, how SARS- CoV-2 may injure pulmonary endothelium has not been well elucidated. Though viral components of SARS-CoV-2 were reported to be occasionally detected in…
Margaret M Stratton · UNIVERSITY OF MASSACHUSETTS AMHERST · 2021 · $10,374 — PROJECT SUMMARY How does a memory outlast the lifetime of the molecule that encodes it? More than two decades ago, Francis Crick had the foresight to speculate that perhaps a multimeric protein could serve as a molecular memory by sharing its activation state with newly synthesized proteins through …